Vigabatrin is approved for the treatment of infantile spasms and focal seizures. In TSC, it is the recommended first-line treatment for infantile spasms. Recent reports and ongoing studies additionally suggest that early vigabatrin treatment, before the onset of clinical seizures, may reduce subsequent overall epilepsy burden and improve long-term developmental outcomes. The potential for vigabatrin-associated visual field loss, however, is a persistent concern of both clinicians and parents who struggle with evaluating treatment benefit and risk when considering treatment with vigabatrin. The 2019 TSC SIG will update members on the
Presidential Symposium: Evidence-Based Treatment for Women with Epilepsy During Reproductive Years: 15 Years of Progress and Future Directions
The reproductive years are a critical time in the lifespan of a female with epilepsy. Treatment choices should be made with consideration of safety during a future potential pregnancy, planned or unplanned. Fortunately, data from animal preclinical studies, pharmacokinetic modeling, detailed observational prospective studies, and large-scale pregnancy registries have provided an abundance of findings, permitting evidence-based treatment of women with epilepsy during pregnancy. The goal is to maintain maternal health and seizure control while minimizing fetal risk for adverse outcomes such as major congenital malformations and neurodevelopmental abnormalities. Future directions
Posters are grouped by general topic category at various times throughout the meeting. Poster authors are available for discussion. In addition, the following special poster sessions offer additional times to interact with authors.
Tours of selected posters led by leading experts in various topic areas.